Flortaucipir F 18 - Avid Radiopharmaceuticals
Alternative Names: 18F-AV-1451; [18F]-T-807; [3H]AV 1451; [F-18]T807; [F18]AV1451; Fluorine 18 AV 1451; LY3191748; T807; TauvidLatest Information Update: 11 Dec 2025
At a glance
- Originator Siemens Medical Solutions
- Developer Avid Radiopharmaceuticals; PeptiDream
- Class Fluorine compounds; Imaging agents; Indoles; Pyridines; Pyridones; Radiopharmaceutical diagnostics; Small molecules
- Mechanism of Action Diagnostic imaging enhancers; Positron-emission tomography enhancers
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Alzheimer's disease
- Phase II Brain injuries; Cognition disorders; Dementia; Depressive disorders; Neurodegenerative disorders; Progressive supranuclear palsy
- Phase I Aphasia
- No development reported Mild cognitive impairment
Most Recent Events
- 25 Jul 2025 Pharmacodynamics data from preclinical studies in Alzheimer’s disease presented at the Alzheimer's Association International Conference 2025 (AAIC-2025)
- 27 Dec 2024 Registered for Alzheimer's disease (Diagnosis) in Japan (IV) (PeptiDream pipeline, March 2025)
- 22 Aug 2024 Registered for Alzheimer's disease (Diagnosis) in European Union, Iceland, Norway, Liechtenstein (IV)